Feb. 8, 2018— Academic experts continue to question claims that the 340B drug discount program is the cause of consolidations of private physician practices and community-based hospitals. They argue the trend toward consolidation is much more complex and due to a series of factors, including changes in reimbursement policies. In the Feb. 8 issue of Forbes magazine, Duke … [Read more...]
Health Policy Experts Question Findings in Controversial NEJM Study
February 2, 2018—A team of independent health policy experts have questioned the major findings in a recent New England Journal of Medicine (NEJM) study critical of the 340B drug pricing program. In its Jan. 24 issue, the journal published a study authored by Sunita Desai, Ph.D., and J. Michael McWilliams, M.D., Ph.D., that raised questions about whether 340B hospitals are … [Read more...]
Flaws in Understanding Intent of 340B Program Lead to Incomplete Conclusions in Study
January 25, 2018—A recent study published in the New England Journal of Medicine (NEJM)[i] suggests that hospital use of the 340B program is “contrary to the goals of the program,” relying on a finding that there is no evidence of hospitals using 340B savings to expand care or lower mortality among low-income patients. This finding is inconsistent with existing research that … [Read more...]